Medical - Devices
Compare Stocks
2 / 10Stock Comparison
SENS vs PODD
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
SENS vs PODD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Devices | Medical - Devices |
| Market Cap | $221M | $10.61B |
| Revenue (TTM) | $35M | $2.90B |
| Net Income (TTM) | $-69M | $303M |
| Gross Margin | 44.7% | 71.0% |
| Operating Margin | -193.5% | 17.5% |
| Forward P/E | — | 23.8x |
| Total Debt | $41M | $1.05B |
| Cash & Equiv. | $40M | $716M |
SENS vs PODD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Senseonics Holdings… (SENS) | 100 | 57.4 | -42.6% |
| Insulet Corporation (PODD) | 100 | 80.2 | -19.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SENS vs PODD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SENS is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth 56.9%, EPS growth 33.6%, 3Y rev CAGR 29.1%
- Lower volatility, beta 2.07, Low D/E 67.0%, current ratio 4.83x
- 56.9% revenue growth vs PODD's 30.7%
PODD carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.68
- 407.8% 10Y total return vs SENS's -91.6%
- Beta 0.68, current ratio 2.78x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 56.9% revenue growth vs PODD's 30.7% | |
| Quality / Margins | 10.4% margin vs SENS's -196.0% | |
| Stability / Safety | Beta 0.68 vs SENS's 2.07 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | -41.6% vs SENS's -59.4% | |
| Efficiency (ROA) | 9.6% ROA vs SENS's -54.7%, ROIC 20.1% vs -324.5% |
SENS vs PODD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
SENS vs PODD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
PODD leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PODD is the larger business by revenue, generating $2.9B annually — 82.3x SENS's $35M. PODD is the more profitable business, keeping 10.4% of every revenue dollar as net income compared to SENS's -196.0%. On growth, SENS holds the edge at +52.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $35M | $2.9B |
| EBITDAEarnings before interest/tax | -$65M | $582M |
| Net IncomeAfter-tax profit | -$69M | $303M |
| Free Cash FlowCash after capex | -$65M | $416M |
| Gross MarginGross profit ÷ Revenue | +44.7% | +71.0% |
| Operating MarginEBIT ÷ Revenue | -193.5% | +17.5% |
| Net MarginNet income ÷ Revenue | -196.0% | +10.4% |
| FCF MarginFCF ÷ Revenue | -184.7% | +14.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +52.0% | +33.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +33.2% | +160.0% |
Valuation Metrics
SENS leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $221M | $10.6B |
| Enterprise ValueMkt cap + debt − cash | $222M | $10.9B |
| Trailing P/EPrice ÷ TTM EPS | -3.23x | 43.44x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 23.78x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.42x |
| EV / EBITDAEnterprise value multiple | — | 18.65x |
| Price / SalesMarket cap ÷ Revenue | 6.27x | 3.92x |
| Price / BookPrice ÷ Book value/share | 3.66x | 7.17x |
| Price / FCFMarket cap ÷ FCF | — | 28.10x |
Profitability & Efficiency
PODD leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
PODD delivers a 21.4% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $-113 for SENS. SENS carries lower financial leverage with a 0.67x debt-to-equity ratio, signaling a more conservative balance sheet compared to PODD's 0.69x. On the Piotroski fundamental quality scale (0–9), PODD scores 7/9 vs SENS's 6/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -113.2% | +21.4% |
| ROA (TTM)Return on assets | -54.7% | +9.6% |
| ROICReturn on invested capital | -3.2% | +20.1% |
| ROCEReturn on capital employed | -83.6% | +18.7% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.67x | 0.69x |
| Net DebtTotal debt minus cash | $641,000 | $335M |
| Cash & Equiv.Liquid assets | $40M | $716M |
| Total DebtShort + long-term debt | $41M | $1.1B |
| Interest CoverageEBIT ÷ Interest expense | -4.49x | 7.39x |
Total Returns (Dividends Reinvested)
PODD leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PODD five years ago would be worth $5,971 today (with dividends reinvested), compared to $1,403 for SENS. Over the past 12 months, PODD leads with a -41.6% total return vs SENS's -59.4%. The 3-year compound annual growth rate (CAGR) favors PODD at -22.0% vs SENS's -26.4% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -9.0% | -46.6% |
| 1-Year ReturnPast 12 months | -59.4% | -41.6% |
| 3-Year ReturnCumulative with dividends | -60.1% | -52.6% |
| 5-Year ReturnCumulative with dividends | -86.0% | -40.3% |
| 10-Year ReturnCumulative with dividends | -91.6% | +407.8% |
| CAGR (3Y)Annualised 3-year return | -26.4% | -22.0% |
Risk & Volatility
PODD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PODD is the less volatile stock with a 0.68 beta — it tends to amplify market swings less than SENS's 2.07 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PODD currently trades 42.6% from its 52-week high vs SENS's 35.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.07x | 0.68x |
| 52-Week HighHighest price in past year | $14.96 | $354.88 |
| 52-Week LowLowest price in past year | $4.79 | $148.31 |
| % of 52W HighCurrent price vs 52-week peak | +35.8% | +42.6% |
| RSI (14)Momentum oscillator 0–100 | 27.0 | 28.5 |
| Avg Volume (50D)Average daily shares traded | 601K | 1.1M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates SENS as "Buy" and PODD as "Buy". Consensus price targets imply 124.3% upside for PODD (target: $339) vs 67.9% for SENS (target: $9).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $9.00 | $339.00 |
| # AnalystsCovering analysts | 16 | 50 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.6% |
PODD leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SENS leads in 1 (Valuation Metrics).
SENS vs PODD: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is SENS or PODD a better buy right now?
For growth investors, Senseonics Holdings, Inc.
(SENS) is the stronger pick with 56. 9% revenue growth year-over-year, versus 30. 7% for Insulet Corporation (PODD). Insulet Corporation (PODD) offers the better valuation at 43. 4x trailing P/E (23. 8x forward), making it the more compelling value choice. Analysts rate Senseonics Holdings, Inc. (SENS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SENS or PODD?
Over the past 5 years, Insulet Corporation (PODD) delivered a total return of -40.
3%, compared to -86. 0% for Senseonics Holdings, Inc. (SENS). Over 10 years, the gap is even starker: PODD returned +407. 8% versus SENS's -91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SENS or PODD?
By beta (market sensitivity over 5 years), Insulet Corporation (PODD) is the lower-risk stock at 0.
68β versus Senseonics Holdings, Inc. 's 2. 07β — meaning SENS is approximately 203% more volatile than PODD relative to the S&P 500. On balance sheet safety, Senseonics Holdings, Inc. (SENS) carries a lower debt/equity ratio of 67% versus 69% for Insulet Corporation — giving it more financial flexibility in a downturn.
04Which is growing faster — SENS or PODD?
By revenue growth (latest reported year), Senseonics Holdings, Inc.
(SENS) is pulling ahead at 56. 9% versus 30. 7% for Insulet Corporation (PODD). On earnings-per-share growth, the picture is similar: Senseonics Holdings, Inc. grew EPS 33. 6% year-over-year, compared to -39. 8% for Insulet Corporation. Over a 3-year CAGR, SENS leads at 29. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SENS or PODD?
Insulet Corporation (PODD) is the more profitable company, earning 9.
1% net margin versus -196. 0% for Senseonics Holdings, Inc. — meaning it keeps 9. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PODD leads at 17. 5% versus -193. 8% for SENS. At the gross margin level — before operating expenses — PODD leads at 71. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is SENS or PODD more undervalued right now?
Analyst consensus price targets imply the most upside for PODD: 124.
3% to $339. 00.
07Which pays a better dividend — SENS or PODD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is SENS or PODD better for a retirement portfolio?
For long-horizon retirement investors, Insulet Corporation (PODD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
68), +407. 8% 10Y return). Senseonics Holdings, Inc. (SENS) carries a higher beta of 2. 07 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PODD: +407. 8%, SENS: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between SENS and PODD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.